CAS 892553-42-3

Etaracizumab

Description:

Etaracizumab is a monoclonal antibody that targets the protein known as vascular endothelial growth factor (VEGF), which plays a crucial role in angiogenesis, the formation of new blood vessels. This characteristic makes Etaracizumab significant in the context of cancer therapy, as it can inhibit tumor growth by preventing the supply of nutrients and oxygen through blood vessels. The substance is designed to bind specifically to VEGF, thereby blocking its interaction with receptors on endothelial cells. This action can lead to reduced tumor vascularization and potentially enhance the efficacy of other cancer treatments. Etaracizumab is part of a broader class of therapeutic agents that leverage the immune system to combat malignancies. Its development is indicative of the ongoing research into targeted therapies that aim to minimize side effects while maximizing therapeutic outcomes. As with many monoclonal antibodies, its administration is typically through intravenous infusion, and it may be associated with specific side effects related to immune modulation.

Formula: Unspecified

Synonyms:

• Vitaxin
• LM 609
• Immunoglobulin G1 (synthetic mouse NSO cell heavy chain variable region fragment), complex with immunoglobulin G1 (synthetic mouse NSO cell light chain variable region fragment)
• Etaracizumab
• Abegrin

Etaracizumab

CAS: 892553-42-3

Etaracizumab (LM 609) is a humanized monoclonal antibody targeting integrin αvβ3, inhibiting angiogenesis and melanoma growth, used in the study of melanoma.

Purity: 96.77% (SEC-HPLC) - 99.32% (SEC-HPLC)

Color and Shape: Liquid

Molecular weight: 144.64 kDa

Ref: TM-T76807

Etaracizumab

CAS: 892553-42-3

An αvβ3 integrin IgG1 monoclonal antibody.

Ref: 3D-CLA1185